Chemokines are not a separate class from cytokines. They are a specialized subfamily within the larger cytokine family, distinguished by their small size, a shared structural fingerprint, and a particular talent for directing cell movement. Historically, chemokines were discovered as cytokines that could guide immune cells toward sites of infection or injury, and the name itself is a portmanteau of “chemotactic cytokine.” That parent-child relationship is the single most important thing to understand before comparing the two, because framing them as rival categories misses how the immune system actually uses them together.
How Chemokines Fit Inside the Cytokine Family
Cytokines are a broad collection of small signaling proteins released by cells to coordinate immune responses and many other biological processes. The group includes interleukins, interferons, tumor necrosis factors, colony-stimulating factors, and chemokines, among others. Each of these subfamilies has its own structural features and preferred signaling pathways, but they all fall under the cytokine umbrella. Chemokines earned their own classification because they share a distinctive set of conserved cysteine residues that no other cytokine subfamily has, and because their primary job is guiding the movement of cells from one location to another.
The chemokine subfamily itself is divided into four groups based on the spacing of those cysteine residues near the front of the protein: CC, CXC, C, and CX3C.1PubMed Central. Chemokines from a Structural Perspective In CC chemokines, the first two cysteines sit right next to each other. In CXC chemokines, a single amino acid separates them. In CX3C, three amino acids sit in between. The lone C subfamily has only one of those initial cysteines. These are not just naming conventions; the cysteine arrangement determines the overall three-dimensional shape, which in turn determines which receptors the chemokine can dock with and which cell types it recruits. The total number of known human chemokines is around 50, each with at least one designated receptor.2Frontiers in Immunology. Perspective: Insights on the Nomenclature of Cytokines and Chemokines
Structural Differences That Matter
If you could zoom in on a chemokine and a typical cytokine side by side, the most obvious difference is size. Chemokines are compact proteins, roughly 8 to 10 kilodaltons, making them among the smallest signaling molecules the immune system produces. Many other cytokines, particularly the interleukins and interferons, are larger and built around a different architectural plan: a four-helix bundle in which four stretches of coiled protein pack together into a roughly cylindrical shape.3PubMed. Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design That four-helix bundle is so widespread that it appears across interleukins, interferons, and growth factors alike.4PubMed Central. Structural analysis of cytokines comprising the IL-10 family
Chemokines do not use that blueprint. Instead, they fold into a compact arrangement anchored by those conserved cysteine residues, which form disulfide bonds that lock the protein into its functional shape. The resulting structure includes a short, flexible region at the front end of the molecule (the N-terminus) that is critical for activating receptors, and a more rigid core that determines binding specificity. This architecture is why chemokines can be grouped by cysteine pattern: the pattern dictates the fold, and the fold dictates which receptor family the molecule talks to.
Different Receptors, Different Signaling Highways
The receptor families used by chemokines and by other cytokines are fundamentally different, and this is where much of their functional divergence originates.
Chemokine receptors belong to the G protein-coupled receptor (GPCR) superfamily. These are proteins that snake back and forth across the cell membrane seven times, forming a channel-like structure. When a chemokine binds to the outside portion, the receptor changes shape on the inside of the cell, triggering a cascade through G proteins that ultimately reorganizes the cell’s internal skeleton and propels it in the direction of the chemokine signal.5PubMed Central. Chemokine receptors and other G protein-coupled receptors The GPCR family is enormous and ancient; it also includes receptors for hormones, neurotransmitters, and sensory signals like light and odor. Chemokine receptors are a specialized corner of this vast family, tuned specifically for immune cell navigation.
Most other cytokines use a different receptor design entirely. Interleukins, interferons, and related cytokines typically bind to receptors that activate the JAK/STAT signaling pathway. More than 50 cytokines rely on this route, which works by flipping on enzymes called kinases inside the cell; these kinases then activate transcription factors that travel to the nucleus and switch genes on or off.6PubMed Central. The molecular details of cytokine signaling via the JAK/STAT pathway The result is a change in what the cell produces or how it behaves, rather than a change in where it goes. A cytokine like IL-6, for instance, can tell a liver cell to ramp up production of acute-phase proteins during an infection; it does not physically pull the liver cell toward the infection site.
This difference in signaling hardware explains why chemokines specialize in directing traffic while other cytokines specialize in giving orders. Both are essential, but they operate through different molecular machinery.
How Chemokines Build a Trail
One of the more elegant features of the chemokine system is the way it creates physical gradients that cells can follow, a bit like a scent trail for a tracking dog. Chemokines do not simply float freely in blood or tissue fluid. They bind to sugar-coated molecules called glycosaminoglycans (GAGs) that are anchored to cell surfaces and embedded in the connective tissue between cells. This binding tethers chemokines in place, creating an immobilized concentration gradient: high near the source of infection or injury, tapering off with distance.7PubMed Central. Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System Immune cells sense the difference in concentration across their own body length and crawl toward the higher end of the gradient, a process called haptotaxis.8PubMed. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses
This gradient mechanism is something that most other cytokines simply do not do. Cytokines like TNF-alpha or IL-1 can certainly diffuse away from the cell that released them and influence nearby cells, but they do not build fixed directional trails through tissue. Their job is to change cell behavior, not to steer cell movement. The chemokine-GAG interaction is a major reason why immune cells arrive at the right place rather than wandering aimlessly through the body.
Pleiotropy and Redundancy
Both chemokines and other cytokines are famous for being confusingly versatile. Two properties dominate: pleiotropy, meaning one molecule can trigger different responses in different cell types, and redundancy, meaning multiple molecules can produce overlapping effects.9PubMed Central. Multifarious determinants of cytokine receptor signaling specificity A single cytokine like IL-6 can promote inflammation in one context and dampen it in another, depending on which cells it reaches and which receptors those cells carry.10PubMed Central. Molecular and cellular factors determining the functional pleiotropy of cytokines
In the chemokine system, redundancy has been a particular headache for drug developers. Multiple chemokines can bind the same receptor, and a single chemokine can bind several different receptors. This means blocking one chemokine or one receptor often does not shut down the pathway because other members step in to fill the gap.11PubMed Central. Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine-mediated leukocyte recruitment That said, researchers increasingly suspect that the “redundancy” label oversimplifies what is happening. In living tissue, the timing, location, and concentration of each chemokine differ in ways that create specificity even when the receptor overlap looks chaotic in a test tube. The real picture is more like an orchestra where several instruments can play the same note, but they are never all playing at the same time or volume.
Roles in Disease
Because cytokines broadly and chemokines specifically are central to immune regulation, both are deeply involved in disease when things go wrong.
Overproduction of pro-inflammatory cytokines like TNF-alpha, IL-1, and IL-6 is a hallmark of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. In these conditions, the immune system misfires, and the cytokine signaling that should calm down after the threat is handled instead stays chronically active, causing tissue damage.12PubMed Central. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases The concept of a “cytokine storm,” where the body floods itself with pro-inflammatory cytokines, gained wide public awareness during the COVID-19 pandemic, though the term applies to severe immune responses in many infections and conditions.
Chemokines, meanwhile, are implicated in a different and particularly unsettling disease mechanism: helping cancer spread. Tumor cells can hijack chemokine signaling to metastasize. By expressing chemokine receptors on their surface, cancer cells can essentially follow chemokine gradients to distant organs, settling in locations where those chemokines are produced. The CXCL12-CXCR4 axis is the most studied example of this: many cancer types express the CXCR4 receptor, and organs like the bone marrow, lungs, and liver produce high levels of CXCL12, which acts as a homing beacon for the tumor cells.13PubMed Central. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion This is one reason certain cancers consistently metastasize to the same organs rather than spreading randomly.
Cytokines Shape Immune Cell Identity
One function that sits squarely in the non-chemokine cytokine camp is determining what kind of immune cell a precursor cell becomes. Helper T cells, which coordinate much of the adaptive immune response, differentiate into specialized subtypes under the influence of specific cytokines. The cytokine environment a naive T cell encounters when it first meets a threat determines whether it becomes a Th1 cell (good at fighting intracellular pathogens), a Th2 cell (focused on parasites and allergy), a Th17 cell (targeting bacteria and fungi at barrier surfaces), or one of several other subtypes.14PubMed Central. Helper T cell differentiation Chemokines do not drive these identity decisions. Their job begins once the T cell has already committed to a subtype and needs directions to the tissue where it is needed.
This division of labor illustrates the broader theme: cytokines set the strategic agenda, while chemokines handle the logistics. A cytokine tells a cell what to become and what to make. A chemokine tells it where to go.
Targeting Cytokines and Chemokines as Therapy
The pharmaceutical industry has had far more success blocking cytokines than blocking chemokines, and the reasons trace back to the structural and signaling differences already described.
Cytokine-targeted therapies have transformed the treatment of autoimmune and inflammatory diseases. Monoclonal antibodies and soluble receptors that neutralize TNF-alpha (drugs like adalimumab and etanercept), IL-6 (tocilizumab), IL-17 (secukinumab), and IL-23 (guselkumab) are now standard treatments for conditions ranging from rheumatoid arthritis to psoriasis to Crohn’s disease.15PubMed. Targeting cytokines to treat autoimmunity These drugs work because the target cytokines are often non-redundant bottlenecks in a disease pathway: remove TNF-alpha signaling, and the inflammatory cascade stalls.
Chemokine receptor antagonists have had a rougher road. The redundancy of the chemokine system means that blocking a single receptor or ligand often does not produce the dramatic clinical improvement seen with cytokine blockers. Animal models of chemokine-driven disease have frequently failed to predict what happens in humans, adding another layer of difficulty.16Nature Reviews Drug Discovery. Chemokine receptor antagonists: overcoming developmental hurdles The limited understanding of how chemokine signaling goes wrong in specific diseases, combined with the broad ligand-binding pockets of chemokine receptors that make it hard to design selective drugs, has slowed progress.17PubMed Central. Latest update on chemokine receptors as therapeutic targets
There are notable exceptions. Maraviroc, a CCR5 antagonist, is used in HIV treatment because the virus uses the CCR5 receptor to enter immune cells. Plerixafor, which blocks CXCR4, is used to mobilize stem cells from bone marrow into the bloodstream for transplant collection. Both drugs succeed because they target a very specific, non-redundant interaction rather than trying to shut down a broad chemokine-driven inflammatory process.
Atypical Chemokine Receptors
Not every chemokine receptor works the way the standard ones do. A group known as atypical chemokine receptors (ACKRs) look structurally similar to the conventional seven-transmembrane GPCRs and bind chemokines with high affinity, but they do not trigger the normal G-protein signaling cascade and do not cause cells to migrate.18PubMed. Atypical chemokine receptors in cancer Instead, ACKRs act as chemokine scavengers: they grab chemokines, internalize them, and break them down, effectively erasing or reshaping the gradient that conventional receptors would follow.19PubMed Central. Atypical chemokine receptors: emerging therapeutic targets in cancer
This scavenging function is crucial for fine-tuning immune responses. Without ACKRs, chemokine gradients would persist too long or spread too widely, attracting immune cells to places where they are no longer needed or, worse, directing them to healthy tissue. ACKRs are now being studied as potential drug targets in cancer, since tumors sometimes exploit these receptors to manipulate their local chemokine environment and evade immune detection.
Beyond Immunity
Both cytokines and chemokines have roles far beyond fighting infections. In the brain, for instance, cytokines like IL-1 beta and TNF-alpha act as neuromodulators, influencing synaptic transmission and playing roles in sleep regulation, mood, and the brain’s response to injury. The chemokine MCP-1 (also called CCL2) is involved in neuroinflammatory responses, and its levels in the brain increase in response to alcohol exposure, contributing to the neuroimmune processes that may underlie alcohol use disorder.20PubMed Central. Ethanol and Cytokines in the Central Nervous System
Chemokines also play housekeeping roles during normal development. They guide the migration of immune cell precursors in bone marrow, direct the positioning of lymphocytes within lymph nodes and the spleen, and help organize tissue architecture during embryonic development. These homeostatic functions operate continuously, not just during illness, which is one reason chemokine-blocking drugs can have unexpected side effects: the drug does not know the difference between a chemokine directing an inflammatory response and the same chemokine maintaining normal tissue organization.
Chemokines and Cytokines as Diagnostic Biomarkers
Measuring the levels of multiple cytokines and chemokines in a blood sample simultaneously, a technique called multiplex cytokine profiling, has become a growing area of clinical research. The idea is that no single cytokine reliably signals a particular disease, but a pattern of several might. In cancer research, profiling panels of cytokines and chemokines in serum have shown promise for early detection. One study measured 24 cytokines, chemokines, and growth factors alongside the standard cancer marker CA-125 and found that the combined panel improved detection of early-stage ovarian cancer compared to CA-125 alone.21Cancer Epidemiology, Biomarkers & Prevention. Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer
In infectious disease, a similar approach has been applied to tuberculosis. One recent study used a sensor platform to measure thirteen proteins in stimulated blood samples and applied machine learning to classify patients as having latent TB infection or not. The system achieved better than 90 percent accuracy for identifying latent TB, with the chemokine IP-10 (also known as CXCL10) emerging as a particularly strong individual signal. For predicting which latent TB patients were at high risk of progressing to active disease, IL-10 and IL-2 were the most informative markers.22PubMed Central. Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification The fact that different biomarkers served different clinical questions within the same disease underscores how the cytokine/chemokine system encodes different kinds of immunological information.
Evolutionary Origins
One of the more surprising recent findings about chemokines is that the molecules we call “chemokines” may not all come from the same ancestral protein. A 2024 analysis found that what the field has been treating as one big family is actually at least five distinct groups of proteins that evolved their chemokine-like properties independently. The canonical chemokines, with their CC and CXC classifications, do form a genuine evolutionary family. But several other proteins that have been given chemokine-style names, including CXCL17, the TAFA proteins, and CYTL1, appear to be unrelated to canonical chemokines and to each other. They landed on similar functions through convergent evolution rather than shared ancestry.23Life Science Alliance. The origin, evolution, and molecular diversity of the chemokine system
This finding has practical implications beyond taxonomy. If some “chemokines” evolved separately and use different structural mechanisms to achieve cell-attracting effects, drugs designed around the canonical chemokine fold may not work against them. It also raises questions about how many other immune signaling molecules have been lumped together based on function when their molecular underpinnings are quite different. The broader cytokine family has always been a somewhat loose grouping, defined more by what the proteins do than by where they came from. The evolutionary evidence suggests that this looseness runs even deeper than previously appreciated.